Your browser is no longer supported. Please, upgrade your browser.
LIFE aTyr Pharma, Inc. daily Stock Chart
aTyr Pharma, Inc.
Index- P/E- EPS (ttm)-4.55 Insider Own0.20% Shs Outstand9.36M Perf Week1.27%
Market Cap38.48M Forward P/E- EPS next Y-3.08 Insider Trans68.92% Shs Float7.02M Perf Month-5.66%
Income-15.70M PEG- EPS next Q-0.73 Inst Own64.40% Short Float0.44% Perf Quarter2.56%
Sales8.50M P/S4.53 EPS this Y56.40% Inst Trans- Short Ratio0.30 Perf Half Y-1.96%
Book/sh6.12 P/B0.65 EPS next Y-32.20% ROA-34.30% Target Price- Perf Year27.80%
Cash/sh5.19 P/C0.77 EPS next 5Y13.00% ROE-52.30% 52W Range2.13 - 7.62 Perf YTD-4.08%
Dividend- P/FCF- EPS past 5Y14.50% ROI-76.80% 52W High-47.51% Beta2.27
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low87.79% ATR0.30
Employees44 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)44.57 Volatility4.80% 8.79%
OptionableNo Debt/Eq0.16 EPS Q/Q110.00% Profit Margin- Rel Volume0.59 Prev Close3.99
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume103.21K Price4.00
Recom2.00 SMA20-7.64% SMA50-3.60% SMA200-0.72% Volume60,815 Change0.25%
Mar-04-20Initiated ROTH Capital Buy $15
Mar-02-20Initiated Oppenheimer Outperform $8
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Sep-07-17Initiated Piper Jaffray Overweight $7
Dec-13-16Downgrade JP Morgan Overweight → Neutral
Dec-16-15Initiated Citigroup Neutral
Jun-01-15Initiated JP Morgan Overweight $44
Jun-01-15Initiated Citigroup Buy $32
Aug-06-20 08:01AM  
Aug-05-20 12:30PM  
Jun-22-20 04:52PM  
Jun-17-20 05:01PM  
Jun-15-20 07:00AM  
Jun-12-20 12:00PM  
Jun-02-20 05:27AM  
May-20-20 08:03AM  
May-12-20 05:25PM  
May-06-20 08:03AM  
May-05-20 08:03AM  
Apr-21-20 08:30AM  
Apr-13-20 12:45PM  
Mar-27-20 07:35AM  
Mar-26-20 05:15PM  
Mar-24-20 08:30AM  
Mar-19-20 04:05PM  
Mar-17-20 08:30AM  
Mar-10-20 08:30AM  
Mar-03-20 08:00AM  
Feb-27-20 08:00AM  
Feb-11-20 06:11PM  
Feb-06-20 09:00AM  
Feb-03-20 11:27AM  
Jan-08-20 10:07AM  
Jan-07-20 09:26AM  
Jan-06-20 08:00AM  
Dec-12-19 08:00AM  
Dec-09-19 11:42AM  
Nov-14-19 04:01PM  
Nov-13-19 08:00AM  
Nov-07-19 08:00AM  
Oct-22-19 08:00AM  
Sep-19-19 06:53PM  
Sep-18-19 08:00AM  
Sep-12-19 03:05AM  
Sep-04-19 08:00AM  
Aug-14-19 08:00AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-10-19 08:00AM  
Jul-01-19 08:00AM  
Jun-28-19 04:05PM  
May-27-19 03:41PM  
May-13-19 04:27PM  
May-06-19 04:58PM  
Apr-16-19 08:00AM  
Apr-11-19 08:00AM  
Apr-10-19 11:05AM  
Apr-08-19 04:00PM  
Mar-28-19 09:00AM  
Mar-25-19 04:16PM  
Mar-21-19 08:00AM  
Mar-18-19 04:46PM  
Mar-11-19 08:00AM  
Mar-04-19 05:36PM  
Feb-27-19 04:00PM  
Feb-21-19 06:20PM  
Feb-05-19 04:05PM  
Jan-30-19 04:00PM  
Jan-16-19 04:00PM  
Jan-15-19 06:23AM  
Jan-02-19 07:37PM  
Dec-21-18 01:51PM  
Dec-04-18 08:00AM  
Nov-29-18 08:06AM  
Nov-28-18 08:16PM  
Nov-21-18 08:50AM  
Nov-13-18 04:21PM  
Nov-08-18 08:00AM  
Oct-17-18 08:00AM  
Oct-15-18 04:30PM  
Sep-27-18 04:05PM  
Sep-20-18 04:38PM  
Aug-30-18 05:51PM  
Aug-14-18 05:03PM  
Aug-08-18 04:05PM  
Jul-31-18 08:00AM  
Jul-26-18 08:00AM  
Jun-26-18 08:00AM  
Jun-08-18 01:46PM  
May-31-18 08:00AM  
May-17-18 07:30AM  
May-15-18 08:06AM  
May-14-18 06:49AM  
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfoot Jill MarieChief Financial OfficerJun 19Buy4.221,8507,8079,153Jun 23 04:27 PM
Shukla SanjayPresident and CEOJun 19Buy4.276,00025,6207,291Jun 23 04:23 PM